Stock Taper
SCREENER COMPARE ANY 2 STOCKS
XERS
XERIS BIOPHARMA HOLDINGS, INC.
NASDAQ
$8.48
▼ DOWN 1.40% (-0.12)

KEY STATISTICS

Market Cap$1.46 B
52w High$10.08
52w Low$5.25
Dividend Yield—
Frequency—
P/E-79.62
Volume1.03M
Shares Out.172.64M

COMPANY

LEADERSHIP

John Shannon
CHIEF EXECUTIVE
John Shannon

COMPENSATION 2026

Salary$742,334
Stock Awards$2,848,000
Incentive Plan Pay$607,971
All Other Comp.$5,664
Total$5,042,584

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 21, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
435

PRICE TARGET

Target High$12.00
Target Low$12.00
Target Median$12.00
Target Consensus$12.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$101.56M
NOV
5
THU

PRICE

$8.48 ▼ DOWN 1.40% (−$0.12)
$8.40$8.47$8.55$8.629:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM8.48

About Xeris Biopharma Holdings, Inc.

https://www.xerispharma.com ↗

Xeris Biopharma develops and markets therapies for endocrinology, neurology, and gastroenterology, including Gvoke, Keveyis, and Recorlev, with pipeline programs utilizing proprietary formulation platforms.

INDUSTRY

Biotechnology

A PRODUCT XERIS BIOPHARMA HOLDINGS, INC. IS KNOWN FOR

Gvoke HypoPen
Gvoke HypoPen

Gvoke HypoPen is the first FDA-approved, ready-to-use autoinjector for treating severe hypoglycemia in diabetics, providing a simpler and faster alternative to traditional glucagon kits.

COMPETITORS

COMPETITOR
AMPH COMPARE
LLY COMPARE
NVO COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$74.06M $83.43M ▲$82.45M ▼$91M ▲
Keveyis$11.94M $12.8M ▲$11.89M ▼$11.68M ▼
Product Other— $651K — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
128
LISTED HERE
25
RANKED BY POSITION SIZE
VTS.AX
0.00% · 5.2M
XSU.TO
0.05% · 4.4M
XPH
1.41% · 960.9K
FYC
0.57% · 959.3K
SCHA
0.03% · 816.4K
FESM
0.09% · 700.7K
JSMD
0.52% · 650.5K
DFAS
0.02% · 353.4K
DBXU.DE
0.03% · 348.4K
PSC
0.07% · 240.7K
BBP
1.56% · 215.6K
BIOT.L
3.33% · 94.0K
RSSL
0.05% · 81.6K
GSSC
0.04% · 48.1K
PILL
0.95% · 27.1K
AVSC
0.01% · 24.9K
SGRW
0.63% · 21.6K
RFLR
0.11% · 12.2K
IBBQ
0.09% · 10.8K
BUYO
0.54% · 10.8K
URTY
0.02% · 7.0K
QSML
0.14% · 2.0K
USFMDN.MX
0.00% · 806
RESM
0.07% · 476
EB
EBI
0.00% · 14

INSTITUTIONAL OWNERSHIP

SHARES OWNED
42.68%
HOLDERS
326
TOP 12 OF 326 · RANKED BY POSITION SIZE
Blackrock, Inc.
14.5M sh · $115.04M
Vanguard Group Inc
11.2M sh · $87.82M
Blackrock Inc.
10.3M sh · $23.25M
D. E. Shaw & Co., Inc.
7.8M sh · $61.81M
State Street Corp
4.8M sh · $38.19M
Geode Capital Management, LLC
4.7M sh · $37.37M
Nuveen, LLC
4.4M sh · $34.73M
Qube Research & Technologies Ltd
4.1M sh · $23.86M
Rosalind Advisors, Inc.
3.2M sh · $18.74M
Morgan Stanley
3.2M sh · $26.21M
Driehaus Capital Management LLC
3.0M sh · $23.4M
Wellington Management Group Llp
2.4M sh · $18.73M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: SEE REMARKS
McCulloch Kevin
Sale · 21.9K shares
2026-08-01
★
DIRECTOR, OFFICER: SEE REMARKS
Shannon John Patrick Jr
Sale · 36.6K shares
2026-08-01
★
OFFICER: SEE REMARKS
Pieper Steven
Sale · 5.0K shares
2026-08-12
★
OFFICER: SEE REMARKS
McCulloch Kevin
Sale · 15.0K shares
2026-08-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 1
BUY 1
NEUTRAL 1
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT HC Wainwright & Co. BUY Piper Sandler NEUTRAL Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
ABCL$11.35COMPARE
CLDX$39.12COMPARE
BCRX$9.82COMPARE
VERA$34.19COMPARE
BHVN$15.41COMPARE
HRMY$39.21COMPARE
IMCR$36.62COMPARE
MAZE$27.44COMPARE